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Psychosis in Alzheimer's Disease
George M. Strickland, M.D. 1 and
Thomas F. Ditzler, Ph.D. 2

Abstract

Much ofthe basic scienceliterature on Alzheimer's Disease (I ill) reflects ongoing research into
pathophysiology and neuropathology. Yet, despite reports qf the association between psychotic
symptoms and A lzheimer's disease, relatively little is known about why such symptoms develop in
certain patients and not in others. Neuroimaging and genetic studies lIlay provide greater
understanding ofthis association and allow clinicians and researchers to prevent, predict and treat
the onset ofpsychotic symptoms in thef uture. Th is paper will review the current literature on the
topic qf psychosis in Alzh eimer's disease andfo cus 0 11 current recommendationsfor interventions b)'
clinicians and caregivers.
METHODOLO GY

A lit erature searc h on th e M edl in e dat ab ase was performed . En glish la nguage
art icles publish ed between 1985-1 999 were cons id e re d. Keyword s "Alzheim er's
Dis ea se", "de me n tia", "psychosis", and "anti-psycho tics" were used in d iffer ent
co mbina tions . Referen ces in th ese a rticles led to furth er referen ces ut ilized in th is
paper. Other sou rces includ e relevant textbook cita tions a nd recent j ournal articles
fro m j ournal s not ava ilab le on t he Medlin e dat ab ase.
INTRODUCTI O N

Alzh eim er's Disea se (AD) re pr es e n ts t he most com mon ca use of d e menti a
accou nting for a bou t 80% of a ll cas es of dem en ti a ( I) . H istoricall y, AD was th e firs t
di sea se in whi ch mi cr oscopi c exam ina tion of th e brai n reveal ed th e histopa th ologic
cha nges of se nile plaqu es, neurofibrill ary tan gles, a nd gra nulovacuo lar dege neration
of neurons (2) . AD is a progr essive, irreversibl e dem enti a that init iall y pr es ents with
m em ory problems followed by lan gu age, math em atical , visuos pat ia l, a nd person ality
d ecline ( I). Th e first sym pto m is usu all y amnesia or t he ina bility to lea rn new
inform ation (I ). Langu age di fficulti es begin wit h word-finding tro ubles followed by
IGeorge 1\1. Str ickla nd, M.D . is a four t h year psych ia t ry resident a t Tripier Arm y Medi cal
C ent er, Hon olulu, Hawaii.
2T homas F. Dit zler , Ph.D. is Director of Research for th e Dep art ment of Psych ia try, Tripier
Army Medi cal Ce nter, Hon olulu , H awai i a nd Lia ison for Ment al Heal th Progra ms, Ce nte r of
Excell en ce in Disast er Managem ent and Hum anit arian Assist an ce, Hon olulu , Hawaii.
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a no m ia a nd a fluent a p has ia (I ). This corre la tes to th e neu rop a t hology that is
g reates t in th e region s post erior to W ernick e's a rea . Eventu all y th e patient becom es
mut e a nd ca nnot co m pre he nd (I) . Visuo sp atial deficit s a nd cog nit ion changes occur
whi ch cor re la te to pari etal and frontal injury (I). During th e end-stages of th e
di sease, th e pati ent is unabl e to swa llow or mobilize a nd d ea th oft en occurs
secondary to sepsis or d eh ydration . This a r t icle will focu s o n psyc hot ic symptoms in
AD , but many ot he r ne uropsychi at ri c features lik e persona lity changes, d epression ,
viole nce, slee p d isturban ce, a nd wa nde ring a re com mon ( I) .
AD causes profound e mo tional suffe ring a nd eco nom ic burden for pati ent s and
th ei r caregivers (3) . In 1997, th e pr eval en ce of AD in t he US was 2.32 million with
a range of 1.09 to 4.58 million (4) . The lifetim e risk of AD in the general population
is roughly 15% (5). Ab out 5% of individual s ove r 65 a nd 15- 25% over 85 will deve lop
AD (6). In th e next 50 years th e pr eval en ce will a lmos t q uad r uple, meaning t hat I
in 45 Am ericans will have th e dis eas e (4). At pr esent , th e a n n ua l incid e nce is
es t ima te d to be 360,000 (4). In th e US, treating AD cos ts 100 billi on do llars a year,
making it the third mos t expe ns ive di sease to treat a fter cancer and heart dis eas e
(7) . Th e di rect a nd tot al cos ts of AD to curre n t a nd fu t ure gene ratio ns are proj ect ed
to reach 536 billi on a nd 1.75 trillio n doll ars res pect ively (8).
PSYCH OTIC SYMPTOMS

So me st udies ha ve shown th at a pp rox ima te ly 30-50% of a ll Alzheim er's pati ents
will eve n t ua lly d evelop psych oti c fea t ures (9, 10). Since a la rge number of AD
pati ents will develop psychotic sym ptoms some t ime ove r th e course of t heir illne ss
proper diagnosis a nd treatm ent is esse nt ia l (II ). Coope r, e t a i, noted th a t psychotic
sym ptoms we re more pr evalent in adva nce d di sease, but th ey ca n prese nt at an y t im e
during th e di sease co urse (9). The link between psych otic sym ptoms a nd AD is well
known . Dr. Aloi s Alzh eim er's initi al case rep ort descri bed sym ptoms of progressive
m em ory loss, personality changes, d elusion al jealousy, para no ia , hall ucina t io ns,
ve rba l outbursts, and di sori ent ation in a 5 1 yea r-old woma n (2, 12). Nonpsychot ic
disruptive behaviors su ch as motor restl essn ess, aggressive out bursts, pacing, and
un cooperativeness are oft en mislab el ed as psych otic o r a re ass u me d to be re lat ed to
th e underlying psychotic process (13). Thus, in a ny AD patient t hat sudd enl y
develops hallucinations or d elusions, oth er cond it ions need to be r uled out and
includ e: drug intoxication, drug withdrawal , physical illn ess, d epression , an d delirium (3). Much of th e managem ent of Alzh eim er's di sease has focu sed o n controlling
th ese nonpsychotic di sruptive beh avioral symptom s, in pa rt beca use t hey a re th e
most di stressin g to ca re give rs a nd a re th e ones most likely to lead to in sti tutionalization ( 14- 16). Yet , this man a gem ent ofte n lead s to t ri al s of antipsychoti cs in
pat ient s with out st rict ly defined psych otic processes ( 13).
Delusions, Hallu cinations, and Misi dentifications

Th e ons et of psychosis in th e AD pati ent can occur a t a ny tim e, but is more lik ely
in lat er sta ge s of th e di seas e (11,17). The specific sym p to ms a re wid e ran gi ng with
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th e most co m mo n being d elusions, hallucination s, a nd m iside ntificat ions (18, 19).
Raskind not ed that d elusions in AD t end to be " u ne la bo ra te d para noid beliefs based
on th e underlying memory d eficit ", th ereby differing from th e "systematized complex d elusions of primary thought dis ord ers" (13). In a re view of s tudies of psychotic
symptoms a mong AD pati ents, d elusions were identifi ed in 10-73% of pat ie nt s, with
most studi es showing a range of 30 -38% ( 18). Delusions of th e persecu tory typ e wer e
th e most co m mon , acc oun t ing for 30 -33% of all delusions ( 18-20). A st udy of 170
pati ents by Deutsch , e t a i, found fort y-three percent of pati en ts had de lusions with
th e following fr equ encies by typ e: pers ecutory, 73%; reference, 14.9%; j eal ousy, 9.5%;
g ra nd iosity, 1.4%; somatic, 1.4% (19).
Th e second most fr equ ently occurring symptom of psych osis in AD is hallucinations. Mu lt ipl e studi es have found th at visual hallucin ation s occur mor e oft en th an
auditory or tactil e typ es (18 ,19 ,21). Deut sch , e t a l, rep ort ed th at 85 % of a ll hall ucinations were visual whi le Wragg a nd ] est e's review rep ort s a me dian fr equ en cy of
13% for a uditory hallucinations (18,19). This patt ern of greate r vis ua l hallucina t ions
is con siste n t with cond it ions like delirium, drug intoxication , drug withdrawal, or
psychosis sec onda ry to a gen eral m edi cal cond it io n. Sc hizop hre nia, schizoaffective
di sorder, a nd mo od di sorders with psychotic features typi call y pr esent with a uditory
hallucinations. Thes e differences should provid e th e clini cian wit h helpful clu es in
th e diagnostic work-up of th e psychotic pati ent.
A third type of psychotic symptom , misidentification synd romes or m ispe rceptions, hav e been not ed in many patients a nd a re conce pt ualize d as a fo r m of d elusion
(20,22 ,23) . However, du e their unique charac te r, th ey ha ve been ca t egor ized apart
from delusions a nd hallueinations (24). Misperceptions result fro m a co m promised
ca pacity to organ ize perceptual infor m a t ion in th e e nviro n me nt. Examples of m isidentifications a re th e bel ief that a stranger is in th e hous e, inability to recog nize
on e 's own reflection, or a beli ef that television shows a re ac tually occ u rring in th e
house . Burns, et ai, d escr ibed a fourth form of mi sid entification , t he e r rone ous
iden tification of a fri end or relative for another person (23) . Mi sid entifi cat ions hav e
be en report ed to occur in a bou t on e-qu art er to on e-third of AD pati en ts wit h a
m edian of 23% (20 ,23,2 5).
Associated Psychiatric Symptoms

Wh en psychosis is see n with oth er neuropsych iatri c sym pto ms lik e dep ression
and agitation, the pati ent is more likely to be in th e advan ced st a ges of th e disease
and mo re diffi cu lt for t he ca re give rs to manage (26) . Levy, et ai , lon gitudinall y
exa mined re curre nc e ra t es of neuropsychiat ri c symptom s in 181 pati ents with AD
over a I-yea r pe riod ( 17) . Recur rence rat es were 95% for psych osis, 93% for ag itation,
and 85 % for depression. Of interest , th e patients that displayed multipl e sym pto ms
at any point during t he study showed great er recurren ce rat es of sym pto ms during
th e remaining pa rt of t he study. Also , if a pati ent di splayed psycho sis upon initi al
evalua t io n, t hey were more likely to d ispl ay agitation and a n accel er at ed cog ni t ive
decline over th e next year. T he patients in t he 76-87 yea r group were not ed to have
more psyc ho t ic symptoms bu t less d ep ression a nd agita tio n than younge r pati en ts.
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Wom en were found to di spl ay more neuropsychi at ric sym pto ms t han the men. This
st udy co nclude d th at once sym pto ms like psych osis, depression, an d agitation begin
that th ey fr equ ently recur and th at vari an ces ex ist by sex a nd age ( 17).
Mu ch of th e lit erature re po rts th at psych otic sym ptoms are associated with
in cr eased cognitive declin e (27-32) . U nde rs ta nd ing th e progression of cognitive
declin e in Alzh eim er's di sease a nd it s associat ion wit h psych osis is im port a n t be cause
psychotic symptoms a re one of th e prima ry re aso ns for instit u tion al iza tion (15,21) .
In suppo rt of this, a st udy of 236 patients by St ern , et a i, foun d t hat pati ent s who
d em on strat ed psychotic symptoms a t th e initi al vis it, incr eased thei r re lative risk or
rea ching an in stitution al ca re rating eq u ivale n t to a nu rsin g hom e by a factor of 1.5
(33). Lerner, e t ai, found th at Alzh eim er's pati ent s wit h visua l ha llucinations
perform ed worse on Mini-M ent al Sta t us Examinations an d d ispl a yed more verbal
outbursts, d elusions, and paranoid ideat ion than those withou t hallu cina tions (29).
In cont ras t to th es e findings, Wragg and] est e, in th eir review of psych osis in AD, cit e
seve ra l studies that found d elusions were more likel y in pa tients wit h high e r
cog nitive scores (18). The expla na tion give n is th at so me level of cogn it ion is
necessary for delusions to occ ur (18,32) . T eri , e t a l, fou nd no d iffere nce in hallucination fr equ en cy a t diffe ring levels of cog nitive fun ct ioning (34).
The rel ation ship between pa rticul ar psych oti c sym p to ms and associat ed behavior s in Alzh ei m er's patie nt s has also been exa m ine d (9, 19,29,35). Cooper, et a i,
rep ort ed that AD pati ent s with psych osis we re twice as likely to be agitat ed (9) .
Lerner, e t a i, found th at visua l hallucin ation s we re pos itive ly associat ed with
agita tion a nd paranoid sym pto ms (29). Other be hav ioral signs and symptom s
associa te d with visua l hallucination s include d a udi tory halluci nat ions, verbal outburst s, delusions, a nd paran oid ideation (29) . In a rep ort by Gi lley, e t aI, hallucin ations were associa te d with ir ritability, di sinhibition , ex trapyramida l symptoms, agitation, a nd d elusions (35). Furth er, Deu tch , et a i, co ncl uded th at th e pr esence or
d elu sions and mi sid entifi cation s m ight be pr edi cti ve of ph ysical aggression (19) .
Cl early, psychotic symptom s are as socia te d with a wid e ra nge of beh avior a l reactions
in Alzh eim er's patient s.
Psychosis and Genetics

Recently there has been a focus on th e ge ne tics of AD, whi ch is a gen et ica lly
het erogen eous disorder associat ed with 3 det erminative ge nes a nd I susceptibility
risk ge ne (5). The det erminative ge ne s are of th e aut osom al dominant type fou nd on
ch ro mosome s I, 14, a nd 2 1 are ea rly-onse t form s th at manifest in t he 40s a nd 50s,
a nd acco u nt for a bout 5% of all ca ses (5). In 1993, a n a po lipoprote in E (APOE)
eps ilon 4 a lle le on ch romosome 19 was di scove red to have susce ptib ility to lat e-onset
AD by incr easing risk a nd d ecr ea sin g age of onse t (5,36). Th e amyloid pr ecursor
prot ein (APP) ge ne is found on chr om osome 2 1 is b rok e n down to a prot ein ,
Bet a-amyloid , t hat is t he major cons tit ue n t of se nile plaqu es (6). Th us, persons with
Down 's Synd ro me over 40 a lmos t uni versall y have pa t hological fea tures of AD at
a u to psy (5) . About 40% of pati ents with AD have a posi tive fam ily histor y for th e
di sorder, but th e 50 % concorda nce rat e in mon ozygotic twins studies po ints to
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e nviron me nta l factors (6,36) . Environmental risk st udies, howeve r, have given varied
results wh en exa m in ing th e a re as of head t rauma , sex, a nd toxins ( 1,5).
Recent research has focus ed on th e relationship between th e APOE genotype
and psyc hiatric symptoms to includ e psychosis (37-4 1). A st udy by H a rwood, et ai,
th at exam ine d 50 I pati ents with probabl e or possibl e AD found a n elevated risk for
psych osis a mong th ose with th e eps ilon 4 alle le (3 7) . Several ot her st ud ies have found
no cor re la tion between th e epsilon 4 alle le a nd psych osis (38-40). Sweet, et ai,
exam ine d th e dopamine receptor ge ne polymorphism s DRD I, DRD2, DRD 3, and
DRD4 for associa tions with th e presence of psychosis in AD (42). They fou nd more
psychosi s in whit e pati ent s with DRDI B21B 2 homozygosit y (42). Also, psyc hosis was
more fr equ ent in all AD pati ents with DRD3 1/ 101' 2/2 hom ozygosit y (42). This study
co ncl ude d that ge ne tic va ria tion in DRD I a nd DRD3 ge nes mi ght mod ify the course
of AD, pr edi sposin g to th e developm ent of psych otic or aggressive sym ptoms (42) .
NEURO IMAG I TG

Ne u ro imaging via compu te d tomogr aphy (C T) or m agn etic resona nce imaging
(M RI) is not di agn osti c for AD , as AD produces no pathogn om oni c cha nges t hat are
see n on conve n tiona l neuroimaging (1,43). However, many expe rts recom mend
ba selin e imaging to ru le out treatabl e form s of d em enti a. Wh en used , non -cont rast
com pu te d tomography to find a t ro phy or diffu se whi te matt er is usu all y sufficient
(43) . le u roa na to rnica l corre la te s of seve r ity of illn ess a nd prese nt a ti on of be havioral
sym ptoms have lon g been known in AD . Zubenko, et ai, showed th a t psych ot ic AD
patients had increased den sities of seni le plaqu es in th e pro subiculum of t he
hippocampus and incr eased d ensiti es of neurofibri llary tangles in th e middl e fron tal
co rte x wh en com pa re d to non-psych otic AD pati ent s a t a uto psy (44). Thei r findings
a re int eresting to not e as ch ro nic idiopathic psych osis of ea rl ie r life is accompanied
by decr eased b lood flow and glucose m etabolism in th e front al co rtex a long wit h ce ll
loss in t he hippocampus (44) .
Posit ron e m ission tomography (PET) a nd sing le e m ission co m pu te d tom ogr aph y (SPEC T) allow for visualization of brain a bnor malit ies via new a pproaches to
conve n tional im aging ( 1,44) . In th e future PET a nd SPECT may a llow for early
pr edi ction of whi ch pati ents will d evelop psychosis. In ge neral, AD ca uses red uced
perfusion or m etabolism in th e region of th e ternporo-pari eto-occipital j unct ion as
vis ualized by SPECT or PET ( 1,45). AD pati ents show redu ced perfusion a nd
m et abolism in th e co rtica l associa tion area s that spa res th e ba sal ga ng lia, th al a mu s,
ce re be llu m , a nd prim ary corte x (3) . Organic psych osis a nd sch izophre nia have been
hypoth esiz ed to be th e result of temporal, pa ri et al , a nd front al lob e dysfun ct ion ;
how eve r, th e ne u ro a na tom ic substrat e for hallucin ations a nd delu sion s is unknown
at this tim e ( 10). Yet , many studi es have found that delusion s cor re la te with
temporal and fronta l lob e dysfuncti on on PET a nd SPEC T (46). Kotrl a, et a i,
exam ine d th e hypoth esis th at psych osis in pati ents with AD was associated with
ce re bra l dysfunction in both th e front al and th e parietal lob es, since virt ua lly all AD
patients have temporal lobe pathology ( 10). They found that delu sional pati ents had
hypope rfusion of t he left fronta l lobe wh ile hallucina ting pa tients had hypoperfusion
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in th e pari etal lobes. This st udy conclude d that psych otic pat ients with AD had
ce re bra l blood flow deficits sign ifican tly different fro m nonpsych otic pati ents with
AD (10) . Thus, AD m ay provid e a model for investigation of th e man ifesta tions of th e
ce re bra l dysfunction that produces psychosi s (10).
MA TAGEMEf\'T

If th ere is mini m al potenti al danger to t he patien t or ot hers, reassurance and
di stracti on is th e t reat ment of choice for psych ot ic AD pa tie n ts (47) . If agitation or
viole n t beh avior is pr esent a nd places the pat ient or caregivers at risk for harm ,
ph a rmacologic treatm ent a long wit h one -on-one care is ofte n req ui red. In som e cas es
restraints may be required but ongo ing usc m ust be j ust ified. Th e number on e goal
is pati ent and st aff sa fe ty a nd com fort. Agit ation , which ofte n accompanies psychosi s,
may be du e to an undiagnosed cond ition suc h as pain , a nx ie ty, hunge r, cons tipation,
or fear of a ba ndo n me n t. Treatm ent here shou ld focu s on reassu rance, att ending to
unm et needs a nd correcting th e und erlyin g cond it ion wit h ca re ful medi ca l eva lua tion (4 7,48).
Neuroleptics

The primary m an agem ent of psychosis in Alzhe ime r's d isease ha s t rad itiona lly
reli ed up on neurol epti c m edi cation s th at have lon g been used to target delusion s,
hallucin ations, and ag ita tion ( 14, 15). The usc of neu rol ept ics in th e elderly population is complex becaus e adverse effec ts arc com mo n a nd se nsitivity to dru g-drug
int eractions is incr eas ed (49). In thi s popul ation th e adve rse effects of grea test
con cern includ e orthostatic hypot ention, delirium, ex t ra- pyra m idal symptoms (EPS),
tardive dyskin esia, urinary ret ention , a nd gla uco ma. Sunde rla nd noted that elde rly
dem ent ed pati ents may be more se ns itive to th e adve rse effects of neurolep tic drugs
and may require lower do ses than non-dem ent ed controls ( I I) . Of particu lar not e is
that th e risk for tardive dyskin esia ('I'D) is 50% in th ose 65 years or older eve n with
shor t-te rm us e (49) . Traditionall y, low do ses of high-pot en cy ag e n ts like hal ope ridol
have been th e initial drugs of choice (50, 51 ). Halop eridol may ca use parkinsonism,
making monitoring for bradykin esia, rigidity, a nd sia lorrhea necessa ry (52) . A
randomized, pla cebo-controll ed do se-comparison trial of hal op eridol for psyc hosis
a nd disruptive behaviors wa s cond ucte d recently by Devan and (53). T his study
indicat ed a favorabl e th erapeutic profile for doses of 2-3 rug/day of hal ope ridol, but
a subg roup of pati ents developed EPS (53 ). The use of low-pot en cy neuroleptics
sho uld ge ne ra lly be avoide d du e to th ei r anti-ch olinergic effects ( 15). Also, patients
with Alzh eim er 's di sea se are a t high risk for fall s or m ay have chronic obst ru cti ve
lung di sease, urinary ret ention , cons tipa tion, or ot her con ditions in whi ch lowpot en cy age n ts a rc con traindica te d ( 14,15).
Th e d evelopm ent of newer m edi cations suc h as risp eridon e and olan zapine,
hav e mad e the drug of initial choice for psychosis a n a rea of d eb at e (54). Med icat ions
such as risperidone hav e gained favor in th e treatm ent of sch izop hrenia a nd ot her
psychotic disorders largely because of safer side -effec t pr ofiles. Risp eridone has
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receiv ed support from so me ge ria t ric clinicians wh o re po rt effec tive ne ss at very low
dos es (0.5-2.0 m g/d ay) (47,55 ). Seve ral st ud ies have shown rispe ridon e to be effectiv e in reducing psych oti c sym ptom s a mo ng d em ent ed pati ent s (25,49,56). Kat z, et
ai , exa m ine d 625 institutionalized pati ent s with d em entia (73% wit h AD) and
significa n t psychosis or beh avioral sym pto ms in orde r to eva lua te t he efficacy and
sa fe ty of risp eridon e in thi s popul ation (56) . Th e pat ient s were randomized in a
doubl e-bl ind , pl aceb o-cont roll ed fash ion to pl aceb o, low-dose (0.5 mg/day), mediumdose ( I mg /day), or h igh-dose (2 mg/day) risperido ne for 12 weeks (56) . The study
concl ude d th at risp eridon e significa n tly im proved sym ptoms of psychosis in severe
d em entia wit h I rug/d ay being an ap propriate dose for most patients (56). With
regards to sa fety, th e fre q ue ncy of EP S was not significan tly great er t han placeb o for
those receivin g I rug/d ay of risp eridon e (56) . C lozapine may prove usefu l for tho se
pati ents se ns itive to EPS, but du e to it s high cos t, wee kly to biweekl y blood
monitoring, and risk for ag ra nu locytosis, it s us e ma y be limit ed in t his popula tion
(55). Tariot reviewed reports of clozapin e use in psych oti c d em ent ed patie nts and
found a mixed pict ure in terms of efficacy a nd side effec ts wit h som e report s showing
a reducti on in psych osis a nd agita tion while ot he rs showing no ben efit (25) . T he
elde rly a re more susce ptible to bru isin g, se da tion, hypote n tion, confus ion, and othe r
a n ti-cho line rg ic effec ts of clozapine . Most of t he published lit era t u re for t he use of
clozapine in thi s population is based on ope n tria ls, chart reviews, a nd case report s.
Thus, th ere is a lack of co n trolled tri al s.
Ol an zapine a nd quetiapine a re newer drugs th at show sim ilar efficacy to
co nve nt iona l neurol eptics a nd do not require blood monitoring (47) . O la nza pine a nd
quetiapin e a re not significantly different from placebo in regards to EPS pr ofiles a nd
ha ve lower risk of tardive dysk en esia. Olanzapine has been shown to be generally
sa fe in sch izoph re n ic populations but m ay be acco mpa nied by mi ld sedat ion, som e
a n ti-cho line rg ic effec ts, di zzin ess a nd weight gai n (57) . Qu etia pi ne has been sh own
to ca use no cha nges in he matological or ECG profi les , required no blood monitoring,
a nd di spl ays low EPS profiles (58). Howeve r, q ue tia pin e demonstrat es substa n tia l
hist amin ic recep tor blockad e with res ulting dizziness, postura l hypot en sion, somnolen ce, a nd we igh t ga in in some pati e nt s (59). An in terim analysis at 12 we eks of an
ongo ing one yea r, ope n trial of qu eti apine in 151 elde rly pat ien ts wit h d e me nt ia (75
pati ents with AD ) and mixed beh avioral problem s, including psych osis, was recently
perform ed (60). Pati ent s received 25 m g to 800 mg/day of qu eti apin e (median
do se = 100 mg/day) with 6% of pati ent s showing EPS. Thi s st udy co ncl uded th a t
qu etiapin e was well tolerat ed a nd associa te d wit h improvem ent in elde rly pat ie nt s
with psychotic di sord ers (60) .
Impl em ent ation a nd dosing of a n ti-psyc ho tics agents is com plex. In general,
non -pharm acologic a lte rnatives sho u ld be atte m p te d first du e to large num bers of
pot ential side -e ffec ts of a nti-psyc ho tics . Gen erall y, side -e ffec t profil es dictat e t he
cho ice of age n t a nd ca n be minimized by usin g th e lowest effect ive dose (47). Dosing
sho uld ge ne ra lly be st art ed at about Ij{ to 1j2 th e usual ad ult dose a nd risks ve rs us
ben efit s mu st be reassessed on a n on going basis. For exa mp le with halop eridol, a
sta rt ing dos e of I mg /day with gradual, upward dos e titration is recomm ended (53).
U se of anticholinergi c age n ts should be avoid ed . Som e authors sugges t it may be
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more beneficial to sche d ule medi cation in a n t icipa t ion of be havior rather than
reacting to symptoms with as need ed m edi cation orders (5 1). In ot he r words, identify
sp ecific times of d ay or ac t ivit ies that pr ecipit at e ce r tain unwant ed be havior and
m edi cat e about on e hour prior to this tim e (25) . Mo st co m mo n ly, t his wou ld be at
ni ght to help fost e r slee p and treat a ny behavior al pr obl em s th at oft en peak at that
tim e (47) .
Alternative Agents

A wide variety of o ther ag ents have been used with som e succe ss, including
lithium , bet a-block ers, se lect ive serotoni n reupta ke in hibitors (SSRI's), trazodon e,
bu spiron e, benzodi a zapines, a nd a nti -convulsants (47,50,5 1). G e nerally, th es e agent s
have been used to t reat agit ation o r aggress ion ra t her t han used to treat psychosis
pe r se . For behavioral con t rol, th e use of t ra zod o ne seems prom ising in se ve ra l
st ud ies ( I I). Tra zod on e give n a t bedtim e reduces nigh tt im e ag itation, whil e lower
doses during th e day help with daytim e ag itat ion (52) . Preli m ina ry dat a sugge st
SSR I's may help a llev ia te ag itat io n (47) . Ant i-convulsants may be indicat ed for
mildly agita te d pati en ts who do not res po nd to an ti-psychotic m edi cation (4 7).
Althou gh a n t i-co nvu lsan ts have fewer side -effects, blood monitoring is required .
Ben zod ia zepines have been show n to cont ro l behaviora l prob lems bett er th a n
placebo but not as we ll as a nt i-psyc ho tics (47). Be nzod ia ze pi nes arc oft en give n in
conj u nc t ion wit h a nt i-psyc ho t ics but sho u ld be used wit h ca u tion in Alzh eim er's
pati ents. G ene rall y, th e use of low-d ose, sh ort-acting agen ts with no active metabolit es (i.e.-oxazepam or loraz epam ) are th e initial d ru gs of cho ice . Unfortun at ely,
side effec ts suc h as a taxia, co nfus io n, a nd seda t ion ma y place th e pat ient at risk for
fa lls . No ne of th e a lte rna tive age n ts have been foun d to target psychosi s but may be
helpful in treating associa te d agita t ion in a ppropria te cases (49) .
C u m mings describes th e t h ree ph armacologic treatments in us e at pr esent in
th e t reatm ent of AD: di sease-mod ifyin g agents, agen ts to manage symptoms of
cog nit ive deficit s, a nd psychotropic age nts for beh avioral dis turbances (52) . Both th e
clinical lit erature a nd th e public have e m braced vitamin E, est roge n, cholin est erase
inhibitors and ging ko biloba as possibl e di sease-m odi fying agents or t rea t m e n ts for
cog nitive d eficits (52) . The pr esent st ra tegy is to treat m ild-t o-m od era t el y affect ed
pati ents with vitamin E and a choline ste rase inhibitor (i.e.- don ep ezil ). Th e us e of
cho lines te rase inhibitors a ppears to slow th e ra t e of cognit ive decline in som e
pati ent s a nd may help to reduce hallucin ation s and d el usio ns (52) . P rincipa l limitat io ns of t hese age nts include th eir expe nse a nd ina bili ty to stop th e course of th e
disease. In lat e r stages of th e di sease, psych ot ro pic agents arc usually necessary and
prolon ga tion of th e illn ess wit h vitam in E may no lo nge r be a th erapeutic goal (5 2).
Post-m en op au sal wome n on es trogen d evelop AD less often , and estrogen give n to
wom en wh o a lready have AD show reduced cognit ive effects (52) . No studi es to dat e
show wh ether or no t those give n es troge n are less lik el y to deve lop psychotic
symptom s. Th ere is so me evide nce th at individu al s ad m iniste re d non-s teroidal
a n t i-infla m m a to ry drugs (NSAIDS) demonstrat e lowe r incid en ce of AD, but littl e
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prosp ective dat a is availa ble (52). No evide nce to dat e has suggest ed th e use of
NSAIDS prevents th e d evel opm ent of psychosis in AD pati ent s.
Non-pharmacologic Approaches

The efficacy of nonpharmacologic interve n tio ns In th e t rea t me n t of psycho sis
remains to be es tablis he d a nd in many in st ances will ha ve on ly limit ed ben efit
(53, 6 1,62) . Yet , so me so urces st ress th at behavioral t herapies are important in th e
m an agem ent of AD as th ey m ay reduce th e occ u r re nce of psych ot ic symptoms in
pati ent s a nd decr ease st ress in ca regive rs (I 4, 15). T ypi call y, specific behavioral
techniqu es a re organized a ro und th ree ce nt ral th em es: I) mo d ification of th e
ph ysica l e nviro n me nt to minimize ex t ra ne ous st im uli a nd maxi m ize pat ie nt di gnity
a nd sa fe ty; 2) training of ca regive rs to com m u nica te effect ively wit h AD pati ents;
a nd 3) pr ovision of e mot ional support , com m u nity resour ce information , a nd respit e
ac t ivit ies for ca regive rs . Modifyin g th e e nviro nmen t may be qu it e simpl e (26) . For
exa m ple, it is oft en he lp ful to a r ra nge t he hom e in a n or de rly an d syst ema tic way
wit h not es to remind th e pati ent wh e re things are (26) . Good lighting, carefu l
placem ent of mirrors, a nd ab sence of tel evision s or radi os can help re d uce d elusions
a nd mi sid entifications (20). Sin ce visio n a nd hearing impairmen t often contribut e to
problems for AD pat ient s it is import ant to e ns u re t he pati ent 's glasses and hearing
a ids a re in goo d o rde r. Assisting non -profession a l ca regivers is vital in th e t rea t me nt
of AD , as non -profession al s provid e 80% of overall care (26). T eaching fami ly
m embers to co m m unica te effec t ive ly wit h th e A D pat ient ca n a me lio ra te some of th e
fru stration pat ients ma y evo ke . Refer ring famil y m embers to th e local chapt er of th e
[at ion a l Alzh eim er's D isease & Rel a t ed D isorde rs Association ca n im prove th ei r
access to co m m unity reso urces a nd ove ra ll qualit y of care (26,52).
If t he pati ent reaches th e point whe re in stitutionali za t ion beco mes necessary,
specia l ca re units a re oft en ava ila ble (20,63) . These uni ts provide a safe, non threat ening env iro n me nt in whi ch ir rel evan t st im uli are reduced (20). In recen t
years suc h unit s have becom e incr easin gly avai la ble a nd may slow th e declin e of
fu nc t iona l ca pacity . A rece n t study of 1228 resi dent s in 48 fa ciliti es with specia l ca re
unit s demon strat ed no stat ist ica lly sig nifica nt di ffere nces in speed of d eclin e from
tradition al unit s; howeve r, th e aut hors concl uded that th es e units mi ght pr ovid e
unm easured ben efits to famili es a nd resid ent s by improving overa ll q uality of
life (63) .
CONC LUSIONS

Th e associa t ion bet ween psych ot ic sym pto ms an d Alzhe ime r's d isease is well
know n, a nd th ese sym ptoms are di st ressi ng to pa ti ents, ca re give rs, and clinicians. It
is also know n th at de lusions, hallucination s, a nd m iside n t ifica t ions occur co m monly
among AD pa t ie nts a nd a re associate d wit h sig nificant morbidity. Controversy
re m ains as to whet her or no t psych ot ic sym ptoms lead to a more ra pid cog nit ive
declin e, but most researc he rs agree th at psych osis is pos itively associa ted with
agita t ion a nd aggression (9, 19,29,35) .

42

J EFFERSON JOURNAL O F PSYCHIATRY

C u r re nt m an agem ent of psych osis ce nters on use of a nt i-psychotic medi cation ,
behavioral th erapy, and famil y ed ucat ion ( 14, 15,20,5 0,5 1). T here is a pau city of
scientific lit erature on th e nonpharm acologic a pproaches to th e managem ent of
psychosi s in AD and th eir overall efficacy is yet to be proven (53,62). W ith regards to
ph armacologic m anagem ent , th e use a nd developm e nt of newe r m ed ica t io ns with
fewer side -e ffec ts a ppears promi sin g (47) . At th e pr esent ti m e t he litera ture lacks a
numbe r of con t rolle d st udies on th e a typ ica l an t i-psyc hotics in AD pati ent s, but it
a ppea rs t ha t more st udies are for t hco m ing. Th e effe cts of spec ia l ca re uni ts on
fu nc t ional outco me in AD is a n a rea th at requires more investigation (63). C ur re nt
Research is now usin g fu nc t io na l neuroimaging to exam in e AD, but neuroan at omic
cor re la tes of psych osis in AD rem ain largely unknown (3,10). Articl es addressin g
po ssibl e differen ces bet ween psych oti c sym p to ms in t he fam ilia l form s a nd th e
susce pt ibility form of AD were not locat ed in thi s review. Th e hop e is t hat more will
be di scovered about possibl e ge ne tic co rre la tes to th e neu ropsychi at ri c symptom s of
AD in th e near future. It is a ppa re nt fro m this review th a t m uch wor k remains in th e
exam ina tion of th e di sease th at Alzhe im er describ ed as, "a pecu liar di sease of th e
ce re bra l co r t ex" (2).
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